Dot1l expression could further stratify ccRCC patients in lower pT stage, Fuhrman grade and SSIGN category, which might redefine the risk stratification of ccRCC patients and guided clinical decisions. This evidence concerns the gene DOT1L and nonpapillary renal cell carcinoma.